A number of small molecule inhibitors of TβRI and related serine threonine kinases have been developed [62, 63] and been shown in a number of different cancer models to block TGFβ responses in tumor cell lines and in cells in the tumor stroma [64, 65]. Here, MARK2 is linked to neoplasm.